Novel therapeutic agents for the treatment of hbv infection

Abstract

The disclosure includes compounds of Formula (I) wherein Z 1 , Z 2 , Z 3 , X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are defined herein. Also disclosed is a method for treating HBV infection.

What is claimed is: 
     
         1 . A compound or a pharmaceutically acceptable salt thereof, wherein the compound is 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         2 . The compound or pharmaceutically acceptable salt thereof according to  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
       
     
     
         3 . The compound or pharmaceutically acceptable salt thereof according to  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
       
     
     
         4 . The compound or pharmaceutically acceptable salt thereof according to  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
       
     
     
         5 . The compound or pharmaceutically acceptable salt thereof according to  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
       
     
     
         6 . The compound or pharmaceutically acceptable salt thereof according to  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
       
     
     
         7 . The compound or pharmaceutically acceptable salt thereof according to  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
       
     
     
         8 . The compound or pharmaceutically acceptable salt thereof according to  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
       
     
     
         9 . A compound of Formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph or tautomer of said compound of Formula (I) or N-oxide thereof: 
       
         
           
           
               
               
           
         
       
       wherein
 R 1  is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, halo, nitro, oxo, cyano, —(CH 2 ) p R a , —OR a , —SR a , —NH(CH 2 ) p R a , —C(O)R a , —S(O)R a , —SO 2 R a , —C(O)OR a , —OC(O)R a , —NR b R c , —P(O)R b R c , —C(O)N(R b )R c , —N(R b )C(O)R c , —SO 2 N(R b )R c , or —N(R b )SO 2 R c , in which said alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl is optionally substituted with one or more R d ; 
 R 5  is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, —(CH 2 ) p R a , —C(O)R a , —S(O)R a , —SO 2 R a , —C(O)OR a , —C(O)N(R b )R c , —SO 2 N(R b )R c , in which said alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl is optionally substituted with one or more R d ; 
 each of p, and q, independently, is 0, 1, 2, 3, 4, 5, 6, 7, or 8; and 
 R a , R b , R c  and R d , independently, is H, D, alkyl, alkenyl, alkynyl, halo, cyano, amine, nitro, hydroxy, C(O)NHOH, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkylamino, oxo, halo-alkylamino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl. 
 
     
     
         10 . The compound according to  claim 9  or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph or tautomer thereof, wherein R 1  is H or alkyl optionally substituted with one or more D, alkyl, alkenyl, alkynyl, halo, cyano, amine, nitro, hydroxy, C(O)NHOH, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkylamino, oxo, halo-alkylamino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl. 
     
     
         11 . The compound according to  claim 10  or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph or tautomer thereof, wherein R 5  is H or alkyl optionally substituted with one or more D, alkyl, alkenyl, alkynyl, halo, cyano, amine, nitro, hydroxy, C(O)NHOH, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkylamino, oxo, halo-alkylamino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl. 
     
     
         12 . The compound according to  claim 11  or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph or tautomer thereof, wherein R 1  is H or alkyl optionally substituted with one or more D, alkyl, halo, alkoxy, alkoxyalkyl, or haloalkyl. 
     
     
         13 . The compound according to  claim 12  or an N-oxide thereof, or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph or tautomer thereof, wherein R 5  is H or alkyl optionally substituted with one or more D, alkyl, halo, alkoxy, alkoxyalkyl, haloalkyl. 
     
     
         14 . A pharmaceutical composition comprising a compound of  claim 1 , or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph or tautomer thereof, and a pharmaceutically acceptable diluent or carrier. 
     
     
         15 . A method of treatment or prophylaxis of HBV, comprising administering to a subject in need thereof an effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt, solvate, polymorph or tautomer thereof.